Are you good more exercise and losing five pounds, but forgot all about making New Year’s resolutions for your science? Ponder the past year’s advances, setbacks, and surprises in AD research, and use them as fodder for new ideas in 2015.
Trials, Therapies, and Diagnostics
Depending on one’s perspective, 2014 was a glass half-empty or half-full. For those expecting approval of a new drug among the various Aß antibodies in the running, the year started out on a low when in January, papers in the New England Journal of Medicine made it official that Phase 3 trials of bapineuzumab and solanezumab had missed their primary goals.
Hey, check out all the engineering jobs. Post your resume today!
